UNSPSC 51281605: Bekanamycin

This classification denotes an aminoglycoside antibiotic with the molecular formula C18H37N5O10, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 15JT14C3GI chemically known as (1r,2s,3s,4r,6s)-4,6-diamino-3-((3-amino-3-deoxy-.alpha.-d-glucopyranosyl)oxy)-2-hydroxycyclohexyl 2,6-diamino-2,6-dideoxy-.alpha.-d-glucopyranoside but generally known as bekanamycin, which bears US NIH Compound Identifier 816.

UNSPSC 51281605 Bekanamycin (Commodity) does not align with the state and local procurement activity posted under this code. The recent opportunities tagged with this code—naloxone and drug deactivation systems (Seminole County, Florida), a therapeutic pharmacy initiative RFI (Texas Health and Human Services Commission), medical and first aid supplies for fire rescue (City of Tampa), and generic multi-source pharmaceuticals and OTC products (Minnesota Multistate Cooperative Purchasing Alliance)—involve naloxone, emergency medical supplies, pharmacy benefit programs, and broad-based pharmaceutical procurement, none of which concern bekanamycin, an aminoglycoside antibiotic. The opportunities represent purchasing of emergency response consumables, pharmacy program infrastructure, and generic pharmaceutical distribution contracts rather than a narrow injectable antibiotic commodity.

State and local procurement activity under this code tag shows no recent activity specific to bekanamycin. The issuing bodies posting opportunities against this code include a county health department (Seminole County), a state health and human services agency (Texas HHS Commission), a municipal fire department (City of Tampa), and a multi-state cooperative purchasing organization (Minnesota MMCAP administering contracts for multiple states including Oregon). Geographic activity spans Florida, Texas, Minnesota, and Oregon, driven primarily by cooperative purchasing mechanisms and municipal emergency services procurement. Recent solicitations include an IFB for naloxone and drug deactivation systems (Seminole County, due July 26, 2023), an RFI on direct-to-manufacturer prescription programs (Texas HHS, due April 3, 2026), an IFB for medical and first aid supplies with a $700,000 estimated value and SLBE set-aside (City of Tampa, due March 13, 2026), and an RFP for generic multi-source pharmaceuticals and OTC products (MMCAP, due March 26, 2026). The code shows a significant mismatch between its nominal scope and the purchasing activity it receives; firms targeting bekanamycin procurement should monitor alternative codes or verify category assignment with issuing bodies before pursuing opportunities listed under this designation.